*Renal Research Group, Kolling Institute of Medical Research, Department of Medicine, University of Sydney, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
Clin Sci (Lond). 2014 May;126(10):685-94. doi: 10.1042/CS20130267.
Diabetic nephropathy is the leading cause of kidney failure and its increasing prevalence and incidence has imposed global socio-economic stress on healthcare systems worldwide. Although historically considered a metabolic disorder, recent studies have established that inflammatory responses are central to the pathogenesis of diabetic nephropathy. TLRs (Toll-like receptors) are a family of pattern recognition receptors responsible for the initiation of inflammatory and immune responses. The regulation of TLR2 and TLR4 have been implicated in the pathogenesis of various kidney diseases, and emerging evidence shows their involvement in the perpetuation of inflammation in the diabetic kidney. The present review focuses on the relative contributions of TLR2 and TLR4 in recognizing endogenous ligands relevant to diabetic nephropathy and their subsequent activation of NF-κB (nuclear factor κB), which results in the synthesis and secretion of pro-inflammatory cytokines and chemokines. Moreover, we discuss the pro-inflammatory signalling pathways of TLR2 and TLR4, in which their interruption or blockade may prove to be important therapeutic targets, potentially translated into clinical treatments for diabetic nephropathy. Currently, inhibitors to TLR2 and TLR4 are undergoing clinical trials in various inflammatory models of disease, but none in patients with diabetic nephropathy. Given the existing literature, there is a fundamental necessity to undertake trials in patients with diabetic nephropathy with a focus on renal end points.
糖尿病肾病是导致肾衰竭的主要原因,其患病率和发病率的不断上升给全球医疗体系带来了巨大的社会经济压力。尽管糖尿病肾病在历史上被认为是一种代谢紊乱,但最近的研究已经证实,炎症反应是糖尿病肾病发病机制的核心。TLRs(Toll 样受体)是一类模式识别受体,负责启动炎症和免疫反应。TLR2 和 TLR4 的调节与各种肾脏疾病的发病机制有关,新出现的证据表明它们参与了糖尿病肾脏中炎症的持续存在。本综述重点介绍了 TLR2 和 TLR4 在识别与糖尿病肾病相关的内源性配体及其随后激活 NF-κB(核因子 κB)方面的相对贡献,这导致了促炎细胞因子和趋化因子的合成和分泌。此外,我们还讨论了 TLR2 和 TLR4 的促炎信号通路,其中它们的阻断或抑制可能被证明是重要的治疗靶点,并可能转化为糖尿病肾病的临床治疗方法。目前,TLR2 和 TLR4 的抑制剂正在各种炎症性疾病模型的临床试验中进行,但在糖尿病肾病患者中没有进行临床试验。鉴于现有文献,有必要在糖尿病肾病患者中进行以肾脏终点为重点的试验。